
-
Germany's AfD dealt blow with right-wing extremist label
-
Trump NASA budget prioritizes Moon, Mars missions over research
-
Hard-right romps through UK polls slapping aside main parties
-
Rangers hire two-time NHL champion Sullivan as coach
-
Haaland on bench for Man City as striker returns ahead of schedule
-
US designates two Haitian gangs as terror groups
-
Lower profits at US oil giants amid fall in crude prices
-
NBA icon Popovich stepping down as Spurs coach after 29 seasons
-
'Devastated' Prince Harry says no return to UK but seeks royal reconciliation
-
Grande scratched from Kentucky Derby
-
Carney vows to transform Canada economy to withstand Trump
-
Prince Harry says he would 'love' to reconcile with family
-
Major offshore quake causes tsunami scare in Chile, Argentina
-
GM cuts shift at Canada plant over 'evolving trade environment'
-
F1 extends deal to keep Miami GP until 2041
-
Popovich mixed toughness and spirit to make NBA history
-
US asks judge to break up Google's ad tech business
-
Trump eyes huge 'woke' cuts in budget blueprint
-
Ruud downs Cerundolo to book spot in Madrid Open final
-
Gregg Popovich stepping down as San Antonio Spurs coach after 29 seasons: team
-
Guardiola to take break from football when he leaves Man City
-
Vine escapes to Tour of Romandie 3rd stage win as Baudin keeps lead
-
Olympic 100m medalist Kerley arrested, out of Miami Grand Slam meet
-
Chile, Argentina order evacuations over post-quake tsunami threat
-
Arteta 'pain' as Arsenal fall short in Premier League title race
-
Hard-right romps across UK local elections slapping down main parties
-
US ends duty-free shipping loophole for low-cost goods from China
-
Renewables sceptic Peter Dutton aims for Australian PM's job
-
Australians vote in election swayed by inflation, Trump
-
Syria slams Israeli Damascus strike as 'dangerous escalation'
-
Grand Theft Auto VI release postponed to May 2026
-
Lawyers probe 'dire' conditions for Meta content moderators in Ghana
-
Maresca confident Chelsea can close gap to Liverpool
-
Watchdog accuses papal contenders of ignoring sex abuse
-
Berlin culture official quits after funding cut backlash
-
US hiring better than expected despite Trump uncertainty
-
EU fine: TikTok's latest setback
-
Stocks gain on US jobs data, tariff talks hopes
-
Barca's Ter Stegen to return from long lay-off for Valladolid trip
-
US hiring slows less than expected, unemployment unchanged
-
Man Utd must 'take risk' and rotate players as they target European glory: Amorim
-
Vatican chimney installed ahead of papal conclave
-
Toulouse's Ramos to miss Champions Cup semi with injury
-
Grand Theft Auto VI release postponed to May 2026: publisher
-
S.African mother found guilty of selling young daughter
-
EU wins post-Brexit fishing row with Britain
-
Activists say drones attacked aid boat bound for Gaza
-
Israel says struck near Syria presidential palace amid Druze clashes
-
Eurozone inflation holds above expectations in April
-
Orgies, murder and intrigue, the demons of the Holy See

AstraZeneca moves some production to US amid tariff threat
British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.
"Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 percent to $2.92 billion.
The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to Trump's sweeping levies on imports from trading partners.
Trump has also imposed a series of sector-specific levies, slapping tariffs on imports of steel, aluminium and autos, before launching a "national security" investigation into pharmaceutical imports.
AstraZeneca could become exposed to US levies on its European-made products but Soriot stressed that the impact would be limited due to the ongoing shift in production.
"The limit of the exposure we have relates to exporting products from Europe to the US," Soriot said on an earnings call.
"We are in the process of shifting the manufacturing of those products to the US," he added.
The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026.
Soriot said earlier in the year that he hoped the US will account for around half of AstraZeneca's global revenue by 2030.
Other pharmaceutical companies have also announced plans to increase investments in the United States.
AstraZeneca reconfirmed its outlook on Tuesday, saying it remains on track to achieve its target of $80 billion in annual revenue by the end of the decade.
Its first-quarter profit in 2025 benefited from strong growth in its cancer drug sales and biopharmaceuticals.
During the quarter, it generated 42 percent of its revenue in the United States, followed by 20 percent in Europe.
G.Haefliger--VB